Clinical data | |
---|---|
ATC code |
|
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C10H19NO2 |
Molar mass | 185.263 g/mol |
3D model (Jmol) | |
|
|
|
|
(what is this?) |
Atagabalin (PD-0200,390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results.